Cellectis acquired the Vectocell® intracellular delivery technology from Diatos to optimize the efficacy of its drug candidates. This platform reportedly improves the performance of a therapeutic compound by enabling specific entry into the target cell compartment or organ in animals and humans.
It is based on the fusion between the therapeutic protein and an antibody-derived peptide that facilitates passive entry into the cell. Experimental data shows that this targeting technique provokes minimal immunogenicity and thus reportedly offers excellent safety.
